OTCMKTS:GOVX
Geovax Labs Stock News
$1.45
+0.0499 (+3.56%)
At Close: May 01, 2024
GeoVax Progresses in Coronavirus (COVID-19) Vaccine Development Program
01:00pm, Wednesday, 18'th Mar 2020
ATLANTA, GA, March 18, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (GOVX), a biotechnology company developing human immunotherapies and vaccines against infectious diseases and c
GeoVax Provides Update on Coronavirus (COVID-19) Vaccine Development Program
06:00pm, Wednesday, 04'th Mar 2020
ATLANTA, GA, March 04, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (GOVX), a biotechnology company developing human immunotherapies and vaccines against infectious diseases and ca
Maharashtra govt to give 5% quota to backward Muslim students
08:23am, Saturday, 29'th Feb 2020
Maharashtra's MVA government plans to bring in a law to provide five percent reservations to backward Muslims in government education institutions.
GeoVax to Present at World Immunotherapy Congress 2020
02:00pm, Thursday, 27'th Feb 2020
ATLANTA, GA, Feb. 27, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (GOVX), a biotechnology company developing human immunotherapies and vaccines against infectious diseases and can
Update: GeoVax Prepared to Advance GOVX-B11 HIV Vaccine to Next Clinical Trial
04:50pm, Thursday, 06'th Feb 2020
ATLANTA, GA, Feb. 06, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (GOVX) (GOVXD), a biotechnology company developing human immunotherapies and vaccines against infectious diseas
GeoVax Prepared to Advance GOVX-B11 HIV Vaccine to Next Clinical Trial
02:00pm, Thursday, 06'th Feb 2020
ATLANTA, GA, Feb. 06, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (GOVX), a biotechnology company developing human immunotherapies and vaccines against infectious diseases and c
GeoVax and BravoVax (Wuhan, China) to Collaborate on Development of Coronavirus Vaccine
03:18pm, Monday, 27'th Jan 2020
ATLANTA, GA, and WUHAN, CHINA, Jan. 27, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (GOVXD), a biotechnology company developing human immunotherapies and vaccines against infecti
GeoVax Announces Reverse Stock Split
02:00pm, Thursday, 23'rd Jan 2020
1:2000 Reverse Split Effective January 24, 2020;Ticker Symbol Changed to GOVXD for 20 Days ATLANTA, GA, Jan. 23, 2020 -- via NEWMEDIAWIRE – GeoVax Labs, Inc. (OTC: GOVX).
GeoVax to Present at World Vaccine & Immunotherapy Conference
02:00pm, Tuesday, 03'rd Dec 2019
Two Separate Presentations to Focus on the Company’s Infectious Disease Vaccines and Cancer Immunotherapy Programs ATLANTA, GA, Dec. 03, 2019 -- via NEWMEDIAWIRE -- GeoVax.
GeoVax Observes 2019 World AIDS Day
02:00pm, Monday, 02'nd Dec 2019
Developing Multiple Strategies Toward Ending the HIV/AIDS Epidemic ATLANTA, GA, Dec. 02, 2019 -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (OTC: GOVX), a biotechnology.
GeoVax to Present at Vaccines R&D Conference
02:00pm, Thursday, 14'th Nov 2019
Presentation to Focus on the Company’s MVA-VLP Platform for Safe and Effective Vaccines for Infectious Diseases and Cancer ATLANTA, GA, Nov. 14, 2019 -- via NEWMEDIAWIRE --.
GeoVax Vaccine Selected to Participate in Development of Potential HIV Functional Cure
02:00pm, Wednesday, 13'th Nov 2019
The proposed clinical trial will enroll 20 HIV-infected adults who are on stable and effective antiretroviral therapy (ART). The therapeutic regimen to be tested involves a combination of vaccination
GOVX: Third Quarter 2019 Results and Update
11:00am, Monday, 11'th Nov 2019
OTC:GOVX GeoVax Labs, Inc. (OTC:GOVX) filed its third quarter 2019 10-Q and issued the accompanying press release on November 7, 2019 providing an operational and financial update on the company’s p
GeoVax Reports 2019 Third Quarter Financial Results and Provides Corporate Update
07:05pm, Thursday, 07'th Nov 2019
The Underlying Value of GeoVax, and the Promise of the Technology...A Comprehensive Review of GeoVax's Various Development Programs ATLANTA, GA / ACCESSWIRE / November 7, 2019 / GeoVax Labs, Inc. (OTC
GeoVax Vaccine To Be Used in a Phase 1 Trial of Genetically Modified Autologous Cell Therapy for HIV
01:00pm, Thursday, 24'th Oct 2019
On October 18, 2019, AGT announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for AGT’s lead HIV program, AGT103-T, a lentiviral v
